Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of DirectorsGlobeNewsWire • 10/16/23
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred StockGlobeNewsWire • 09/18/23
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.GlobeNewsWire • 12/12/22
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene ImplantPRNewsWire • 07/05/22
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.GlobeNewsWire • 06/10/22
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.GlobeNewsWire • 04/25/22
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-MarketPRNewsWire • 02/02/22
Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021PRNewsWire • 11/08/21
Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing CountriesPRNewsWire • 10/25/21
Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License AgreementPRNewsWire • 10/12/21
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic PruritusPRNewsWire • 06/23/21
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development ProgramPRNewsWire • 02/01/21